La terapia del TEV nel paziente oncologico nell'era dei DOAC

Size: px
Start display at page:

Download "La terapia del TEV nel paziente oncologico nell'era dei DOAC"

Transcription

1 XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro Emostasi e Trombosi Ospedale Papa Giovanni XXIII, Bergamo

2 Cancer and VTE Patients with cancer have a 4 7 fold increased risk for VTE as compared to non-cancer patients; 15 20% of all VTE cases occur in patients with cancer. VTE in cancer patients is associated with important complications, including an 8 10% annual risk of bleeding with anticoagulant therapy and an annual 21 27% risk of VTE recurrence. Falanga et al. Curr Opin Hematol 2014; Agnelli et al. JTH 2011; Lee A., 2013

3 Important Consequences of VTE in Cancer Increased morbidity Hospitalization Anticoagulation Postphlebitic syndrome Increased mortality (worse overall survival outcome) Increased risk of recurrent VTE (21% vs 7% in non cancer patients) Bleeding complications (2 times higher during anticoagulation) Cancer treatment delays Increased healthcare costs

4 Optimising treatment of VTE in the cancer patients Treatment Recurrent VTE Bleeding Quality of life

5 ASCO 2013 & Update 2014: Clinical Practice Guideline Treatment 1. LMWH is preferred over UFH for the initial 5 to 10 days of anticoagulation for the cancer patient with newly diagnosed VTE who does not have severe renal impairment (defined as creatinine clearance < 30 ml/min). 2. For long term anticoagulation, LMWH for at least 6 months is preferred due to improved efficacy over Vitamin K antagonists. Vitamin K antagonists are an acceptable alternative for long-term therapy if LMWH is not available. 3. Anticoagulation with LMWH or Vitamin K antagonist beyond the initial 6 months may be considered for select patients with active cancer, such as those with metastatic disease or those receiving chemotherapy. Lyman GH et al, JCO 2013

6 LMWH versus Vitamin K Antagonist: Long-term Treatment in Cancer Patients Study Pt, N Long-term Treatment Recurr. VTE, % Major Bleed, % Death, % P value Meyer 2002 Lee Warfarin Enoxaparin 1.5 mg/kg Warfarin Dalteparin 200/150 IU/kg Warfarin NS Deitcher 2006 Hull Enoxaparin 1.0 mg/kg Enoxaparin 1.5 mg/kg Warfarin NS 100 Tinzaparin 175 IU/kg Meyer G, et al. Arch Intern Med. 2002:162: ; Lee AY, et al. N Engl J Med. 2003;349: ; Deitcher SR, et al. Clin Appl Thromb Hemost. 2006:12: ; Hull RD, et al. Am J Med. 2006;119:

7 Pooled analysis of the bleeding risk of LMWH and VKA in patients with cancer Minor bleeding Major bleeding Akl et al, Cochrane rev 2011

8 Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: a Randomized Clinical Trial The CATCH Study: randomized, open label, multicenter, phase III trial aimed to assess the efficacy of tinzaparin in preventing recurrent VTE compared with warfarin. Experimental design: patients were randomized to receive tinzaparin 175 IU/kg once daily for 6 months patients were randomized to receive initial tinzaparin 175 IU/kg once daily for 5 10 days overlapped and followed by dose-adjusted warfarin (target INR ) for 6 months Primary efficacy: recurrent VTE verified by objective, standard imaging Primary safety: major bleeding A.Y.Y. Lee et al. JAMA 2015

9 Recurrent venous thromboembolism Results 10,5% A.Y.Y. Lee et al. JAMA 2015 Major bleeding 7.2% HR: 0.89 [95% CI ; P=0.77] HR: 0.65 [95% CI 0,41-1,03; P=0.07] All-Cause Mortality 34.7% 32.2% HR: 1.08 [95% CI ; P=0.54] In patients with active cancer and acute symptomatic VTE, full-dose tinzaparin (175 IU/kg daily) versus warfarin for 6 months: - did not significantly reduce the composite measure of recurrent VTE - and was not associated with reductions in overall mortality or major bleeding, - but was associated with a lower rate of clinically relevant non major bleeding.

10 LMWH is recommended for the initial 5 to 10 days of treatment of established VTE as well as for long-term secondary prophylaxis for at least 6 months.

11 Limitations of LMWH Therapy One randomized trial published showing superiority over warfarin in efficacy recurrent thrombosis and major bleeding still significant lack of long-term data beyond 12 months once-daily subcutaneous injections are uncomfortable and difficult to maintain long-term expensive compared with warfarin LMWH may cause toxicity in patients with renal failure.

12 Direct Oral Anticoagulants (DOACs) FONDAPARINUX RIVAROXABAN APIXABAN EDOXABAN Prothrombinase Xa, Va lipid DESIRUDIN ARGATROBAN BIVALIRUDIN Factor IIa Inhibitors (XIMELAGATRAN) Factor Xa Inhibitors Prothrombin Thrombin DABIGATRAN Platelet activation Fibrin formation Fibrinolysis inhibition Cellular effects

13 DOAC in Patients with Cancer The new oral anticoagulants offer an attractive option because of their oral administration, fixed-dose, and lack of routine laboratory monitoring. The results of phase III trials support the efficacy and safety of the new oral anticoagulants in the management of VTE. However, generalizing these findings to cancer patients with VTE is difficult since very few cancer patients were included.

14 The DOAC and the Treatment of VTE Cancer subgroup analysis from phase III randomized controlled trials comparing DOACs vs conventional treatment after VTE 1. Schulman et al. New Engl J Med Schulman ASH Buller et al. New Engl J Med Buller et al. New Engl J Med Agnelli et al N Engl J Med Hokusai N Engl J Med 2013; Raskob ASH Trials included very few patients with malignant disease. The strict inclusion criteria limited patients with end-organ dysfunction (e.g., renal and liver dysfunction) and elevated risk of bleeding from enrolling, resulting in an overall study population likely not-representative of patients with advanced cancer. Wharin C. and Tagalakis V. Blood Reviews 2014

15 DOACs and Treatment of VTE There are insufficient data to show that DOACs are non-inferior to warfarin in patients with cancer. The small number of highly selected cancer patients in these studies precludes the extrapolation of the available results to the general oncology population. A head-to-head comparison of LMWH with DOACs is necessary to determine if DOACs is an acceptable alternative for the treatment of cancer-associated thrombosis. A. Lee and M. Carrier. Thromb Res 2014

16 Efficacy and safety of DOACs in patients with active cancer Use of DOAC and major bleeding Use of DOAC and clinically relevant bleeding The efficacy and safety profile of DOAC for VTE treatment in patients with cancer is similar to that observed in patients without cancer. A favorable trend toward reduction of recurrent VTE was observed without concern in terms of clinically relevant bleedings. Vedovati et al. CHEST 2015

17 The risk of recurrent VTE (A) and major bleeding (B) in cancer patients The most important results of this study are the RRs of 0.66 (95% CI ) for recurrent VTE and 0.94 (95% CI ) for major bleeding and clinically relevant non-major bleeding, indicating that both the efficacy and safety of NOACs in cancer patients were at least comparable to those of VKAs. Van der Hulle et al. JTH 2015

18 Oral apixaban for the treatment of VTE in cancer patients: results from the AMPLIFY trial The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute VTE. Patients with symptomatic VTE were randomized to a 6-month course of apixaban or enoxaparin followed by warfarin. The primary efficacy outcome and principal safety outcome were recurrent VTE or VTE-related death and major bleeding, respectively. G. Agnelli et al. JTH 2015

19 Results The results of this subgroup analysis suggest that apixaban is a convenient option for cancer patients with VTE. However, additional studies are needed to confirm this concept and to compare apixaban with LMWH in these patients. G. Agnelli et al. JTH 2015

20 Long-term treatment of VTE with NOACs: patients with active cancer In six randomized controlled on treatment of VTE a total of 1227 patients with active cancer were enrolled. M. Verso, G. Agnelli, P. Prandoni. Intern Emerg Med 2015

21 Discussion The preliminary results of trials on long-term VTE treatment suggest that DOAC could be an attractive alternative to conventional anticoagulation in patients with active cancer. However, further clinical trials in patients with active cancer should be performed to confirm these results. In particular, studies should be performed with LMWH as comparator, and should probably investigate different doses of DOAC to determine the best clinical benefit in the treatment of VTE in patients with cancer. M. Verso, G. Agnelli, P. Prandoni. Intern Emerg Med 2015

22 Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis Baseline characteristics M. Carrier et al. TR 2014

23 Recurrent VTE Major bleeding DOAC vs. VKA DOAC vs. VKA LMWH alone vs. VKA LMWH alone vs. VKA M. Carrier et al. TR 2014

24 Results Compared with VKA, LMWH was associated with a significant reduction in the risk of recurrent VTE (HR: 0.52; 95% CI: 0.36 to 0.74) without a significant increase in major bleeding episodes (RR: 1.06; 95% CI: 0.5 to 2.23). In contrast, treatment using DOACs was associated with a non-significant lower risk of recurrent VTE (RR: 0.66; 95% CI: ) and major bleeding episodes (RR: 0.78; 95% CI: 0.42 to 1.44) In summary, LMWH monotherapy should be used for the treatment of acute cancer-associated thrombosis. This review is in-line with current clinical practice guidelines and further recommendations regarding the use of DOACs cannot be supported until trials comparing them to LMWH are conducted. M. Carrier et al. TR 2014

25 Patients with cancer have multiple factors to consider: They are at high risk for hemorrhage for reasons including chemotherapy-induced thrombocytopenia or receipt of antiangiogenic therapy. Limited trial level data are available to clearly define the role of DOAC in patients with cancer. DOAC may cause drug interactions with chemotherapeutic agents, which may result in less efficacy and higher bleeding than that observed in patients without cancer Sardar et al. Am J Therap, 2014

26 Drug Interactions inhibitors and inducers of P-glycoprotein and CYP3A4: antifungals* ritonavir* amiodarone dronederone* quinidine tamoxifen anastrozole lomustine cyclophosphamide bicalutamide* abiraterone* imatinib* & TKIs cyclosporine* tacrolimus Inhibitors Inducers rifampicin phenytoin carbamazepine phenobarbital dexamethasone* prednisone* vemurafenib* paclitaxel* doxorubicin etoposide vinblastine St. John s wort Short & Connors 2014; Lee. Blood 2013.

27 Use of novel oral anticoagulants is not currently recommended for patients with malignancy and VTE.

28 Discussion: DOACs for treatment of CAT The novel anticoagulant drugs seem to be more convenient, as they are orally administered at a fixed dose without routine laboratory monitoring and seem to have fewer drug interactions, in particular with chemotherapeutic agents. However, these drugs may have a potential limitation in cancer patients who suffer abnormal liver function and severe renal impairment or have poor attitude to oral intake.

29 Conclusions: VTE treatment in Cancer Patients Treatment of CAT could be improved with oral agents over LMWH use Current evidence does not yet support the use of DOACs in patients with active cancer Properly designed cancer-specific trials are needed

30 DOAC Clinical Trials for treatment of Cancer-associated VTE RIVAROXABAN: Select-d phase 3, 2-phase randomized, multicentre study in treatment open label dalteparin vs rivaroxaban x 6 mos placebo vs rivaroxaban in patients with residual vein DVT at 6 12 mos Rivaroxaban trial phase 4 multicentre, open-label, study in treatment single arm prospective cohort treated with rivaroxaban x 6 mos EDOXABAN: Edoxaban trial phase 3 multicentre trial in treatment of CAT edoxaban vs dalteparin x 6 mos Hokusai VTE-Cancer Study

31 Hokusai VTE-cancer study The Hokusai VTE cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer. Outcomes: the composite primary outcome of recurrent VTE and major bleeding during a 12-month study period. van Es et al., Thromb Hem 2015

32

My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?

My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research

More information

Cancer Associated Thrombosis An update.

Cancer Associated Thrombosis An update. Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID

More information

New oral anticoagulants and Palliative Care.

New oral anticoagulants and Palliative Care. New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway

More information

incidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2

incidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2 CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the

More information

Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School

Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer

More information

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017 Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in

More information

Cancer Associated Thrombosis

Cancer Associated Thrombosis Cancer Associated Thrombosis Can we use DOACs? D R. C Y N T H I A W U MD F R C P ( C ) D I V I S I O N O F H E M A T O L O G Y F A M I L Y P H Y S I C I A N S A N D C A N C E R C O N T R O L A P R I L

More information

DOACs and CAT. 05 May 2017 NTW St Thomas Hospital

DOACs and CAT. 05 May 2017 NTW St Thomas Hospital DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen

More information

Management of Cancer Associated VTE

Management of Cancer Associated VTE Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

New Oral Anticoagulant Drugs in the Prevention of DVT

New Oral Anticoagulant Drugs in the Prevention of DVT New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X

More information

Cancer Associated Thrombosis Review and Update. Family Practice Oncology CME Day November 21 st 2015 Erica Peterson

Cancer Associated Thrombosis Review and Update. Family Practice Oncology CME Day November 21 st 2015 Erica Peterson Cancer Associated Thrombosis Review and Update Family Practice Oncology CME Day November 21 st 2015 Erica Peterson Disclosures No conflicts of interest to declare Objectives To review evidence in cancer-associated

More information

Updates in venous thromboembolism. Cecilia Becattini University of Perugia

Updates in venous thromboembolism. Cecilia Becattini University of Perugia Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15

More information

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno

More information

New Anticoagulants Therapies

New Anticoagulants Therapies New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations

More information

Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1

Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate

More information

Obesity, renal failure, HIT: which anticoagulant to use?

Obesity, renal failure, HIT: which anticoagulant to use? Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have

More information

Updates in Management of Venous Thromboembolic Disease

Updates in Management of Venous Thromboembolic Disease Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures

More information

DOACs in SPECIAL POPULATIONS

DOACs in SPECIAL POPULATIONS DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

Cancer associated thrombosis. 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK

Cancer associated thrombosis. 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK Cancer associated thrombosis 17 th November 2016 Simon Noble Clinical Professor Palliative Medicine Cardiff University Wales, UK Today What is VTE? How does CAT differ? Initial anticoagulation Anticoagulation

More information

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular

More information

ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS

ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN THE AGE OF DIRECT ORAL ANTICOAGULANTS Chee Yen Lin Consultant Haematologist NCIS Haematology National University Hospital Singapore Nomenclature direct oral anticoagulant

More information

I nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo

I nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo I nuovi anticoagulanti orali nella trombosi venosa profonda Terapia della TVP Fulvio POMERO Medicina Interna S. Croce e Carle Cuneo 1 2 3 Poor VKA control (first 90 days) Good VKA control (first 90 days)

More information

The clinical relevance of AMPLIFY programme

The clinical relevance of AMPLIFY programme Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer

More information

Update on the Management of Cancer Associated VTE

Update on the Management of Cancer Associated VTE Update on the Management of Cancer Associated VTE Jean M. Connors, MD 2018 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Associate Professor

More information

Cancer and Venous Thromboembolism

Cancer and Venous Thromboembolism 125 34 Cancer and Venous Thromboembolism Stephan Moll, MD University of North Carolina Chapel Hill, NC GASCO, Atlanta Sept 8 th, 2017 Disclosures Consultant: Speaker bureau: none Janssen, Boehringer-Ingelheim,

More information

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives

More information

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support

More information

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole

More information

Cancer associated thrombosis

Cancer associated thrombosis Cancer associated thrombosis Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University Take home messages 1. Clots are cool

More information

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN

More information

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One

More information

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven

More information

Evidences for real-life use in fragile patients: Renal failure and cancer

Evidences for real-life use in fragile patients: Renal failure and cancer Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences

More information

Choosing and Managing Direct Oral Anticoagulants (DOACs)

Choosing and Managing Direct Oral Anticoagulants (DOACs) Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from

More information

New areas of development for the direct oral anticoagulants

New areas of development for the direct oral anticoagulants New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory

More information

Venous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH

Venous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis

More information

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew

More information

New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical trials.

New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical trials. Interactions cellulaires tumorales et leur environnement et réponses aux agents anticancéreux. New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical

More information

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened

More information

The spectrum of clinical outcome of PE

The spectrum of clinical outcome of PE Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome

More information

Thromboembolism and cancer: New practices. Marc Carrier

Thromboembolism and cancer: New practices. Marc Carrier Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant

More information

PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES

PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center

More information

Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.

Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study. Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research

More information

VENOUS THROMBOEMBOLISM, CANCER AND CKD ANOTHER TRIAD TO MANAGE

VENOUS THROMBOEMBOLISM, CANCER AND CKD ANOTHER TRIAD TO MANAGE VENOUS THROMBOEMBOLISM, CANCER AND CKD ANOTHER TRIAD TO MANAGE I. ELALAMY Service d Hématologie Biologique HOPITAL TENON PARIS INSERM UMR U938 DISCLOSURES Conferences Clinical Studies Board Sanofi X X

More information

ADVANCES IN HEMATOLOGY

ADVANCES IN HEMATOLOGY ADVANCES IN HEMATOLOGY Current Developments in the Management of Hematologic Disorders Section Editor: Craig M. Kessler, MD Are Direct Acting Oral Anticoagulants Ready for Prime-Time Use in Cancer-Related

More information

New Strategies and New Data- Beyond Guidelines

New Strategies and New Data- Beyond Guidelines New Strategies and New Data- Beyond Guidelines Anthony Maraveyas GESCAT Lisbon 13 th October 2018 G.MA.GM.XA.12.2017.1962 Conflict of Interest Statement 2 u Research Support: Bayer, Boehringer Ingelheim,

More information

With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis

With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

An Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London

An Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations

More information

Cancer Associated Thrombosis

Cancer Associated Thrombosis Cancer Associated Thrombosis Pantep Angchaisuksiri, MD Professor of Medicine Mahidol University, Thailand Adjunct Associate Professor University of North Carolina, Chapel Hill, USA Piccioli A. J Thromb

More information

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,

More information

New Antithrombotic Agents DISCLOSURE

New Antithrombotic Agents DISCLOSURE New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What

More information

Anticoagulation: Novel Agents

Anticoagulation: Novel Agents Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical

More information

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005 Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.

More information

Abstract. Background. Methods

Abstract. Background. Methods Abstract Background Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

More information

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

Clinical Guideline for Anticoagulation in VTE

Clinical Guideline for Anticoagulation in VTE Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that

More information

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin 1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,

More information

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review

More information

Non commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background

Non commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as

More information

Treatment Options and How They Work

Treatment Options and How They Work Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the

More information

Prophylaxie primaire sur le patient ambulatoire. Marc Carrier

Prophylaxie primaire sur le patient ambulatoire. Marc Carrier Prophylaxie primaire sur le patient ambulatoire Marc Carrier Marc Carrier In compliance with COI policy, SSVQ requires the following disclosures to the session audience: Research Support/P.I. Employee

More information

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016 Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015

More information

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of

More information

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational

More information

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal

More information

Treatment of cancer-associated venous thromboembolism by new oral anticoagulants: a meta-analysis

Treatment of cancer-associated venous thromboembolism by new oral anticoagulants: a meta-analysis Original Article Page of 9 Treatment of cancer-associated venous thromboembolism by new oral anticoagulants: a meta-analysis Satyanarayana R. Vaidya, Sonu Gupta, Santhosh R. Devarapally, Department of

More information

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

Are guidelines for anticoagulation useful in cancer patients?

Are guidelines for anticoagulation useful in cancer patients? Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation

More information

Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy

Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE

More information

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions

More information

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker

More information

Anticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital

Anticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients

More information

Drug Use Criteria: Direct Oral Anticoagulants

Drug Use Criteria: Direct Oral Anticoagulants Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed

More information

Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations

Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations EVOLVING ISSUES IN ANTICOAGULATION Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations Nick van Es 1 and Harry R. Büller 1 1 Department of Vascular Medicine, Academic Medical

More information

Update on thrombosis 13/07/2017. To focus on

Update on thrombosis 13/07/2017. To focus on Update on thrombosis Oxford Advanced Course 2017 Simon Noble Clinical Professor Palliative and Supportive Medicine Cardiff University Wales, UK To focus on Changing thrombogenicity of cancer What is the

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

Profilassi e trattamento del tromboembolismo venoso nei pazienti con neoplasia: le nuove linee guida

Profilassi e trattamento del tromboembolismo venoso nei pazienti con neoplasia: le nuove linee guida Profilassi e trattamento del tromboembolismo venoso nei pazienti con neoplasia: le nuove linee guida Anna Falanga Dipartimento di Medicina Trasfusionale ed Ematologia Centro Trombosi ed Emostasi Ospedale

More information

Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE)

More information

Management of Cancer- Associated Thrombosis. Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University

Management of Cancer- Associated Thrombosis. Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Management of Cancer- Associated Thrombosis Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer Bayer Sanofi Leo Pharma

More information

New Antithrombotic Agents

New Antithrombotic Agents New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic

More information

Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE

Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications

More information

New Oral Anticoagulants Prevention and Treatment of DVT and PE

New Oral Anticoagulants Prevention and Treatment of DVT and PE New Oral Anticoagulants Prevention and Treatment of DVT and PE Grigoris T Gerotziafas Groupe de Thrombose Equipe de recherche ER2UPMC Interactions cellulaires tumorales et leur environnement et réponses

More information

Reversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding

Reversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)

More information

Cancer Associated Thrombosis Approach to VTE recurrence

Cancer Associated Thrombosis Approach to VTE recurrence Cancer Associated Thrombosis Approach to VTE recurrence http://anticoag-pass-s2d.fr/ Isabelle Mahé Hôpital Louis Mourier Service de Médecine Interne APHP-Université Paris 7 EA REMES 7334-UMR 1140 France

More information

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

Do s and Don t of DOACs DISCLOSURE

Do s and Don t of DOACs DISCLOSURE Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier

More information